NCT00260988View on ClinicalTrials.gov

A Comparison of Dalteparin and Tinzaparin for Prevention of Blood Clots in Hemodialysis Patients on Oral Anticoagulants Having Surgery

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

29

Participants

Timeline

Start Date

October 31, 2003

Primary Completion Date

November 30, 2008

Study Completion Date

November 30, 2008

Conditions
ThromboembolismHemodialysis
Interventions
DRUG

Fragmin (dalteparin)

200 IU/Kg/Day administered subcutaneously for three days prior to but not including the day of the surgery

DRUG

Innohep (tinzaparin)

175 IU/kg/Day administered subcutaneously for three days prior to but not including the day of the surgery

Trial Locations (2)

L8N4A6

St. Joseph's Healthcare, Hamilton

K1Y4E9

The Ottawa Hospital, Ottawa

Sponsors

Collaborators (1)

LEO Pharma
All Listed Sponsors
collaborator

LEO Pharma

INDUSTRY

lead

Ottawa Hospital Research Institute

OTHER

NCT00260988 - A Comparison of Dalteparin and Tinzaparin for Prevention of Blood Clots in Hemodialysis Patients on Oral Anticoagulants Having Surgery | Biotech Hunter | Biotech Hunter